{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T07:00:23Z","timestamp":1782025223719,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.cllc.2021.06.013","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T12:22:52Z","timestamp":1625487772000},"page":"e17-e28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology"],"prefix":"10.1016","volume":"23","author":[{"given":"Sara","family":"Manglaviti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Brambilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Proto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"De Toma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Occhipinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viscardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Beninato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Zattarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lobefaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4637-9821","authenticated-orcid":false,"given":"Giacomo","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4345-3355","authenticated-orcid":false,"given":"Achille","family":"Bottiglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Apollonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sottotetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Trevisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ganzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo G.M.","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Chiara","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsela","family":"Prelaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.cllc.2021.06.013_bib0001","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab vs. Chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.06.013_bib0002","unstructured":"T. S. K. Mok, Y. L. Wu, I. Kudaba, et\u00a0al., Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomized, open-label, controlled, phase III trial Lancet 393 (2019) 1819\u20131830, http:\/\/dx.doi.org\/10.1016\/S0140-6736(18)32409-72019"},{"issue":"21","key":"10.1016\/j.cllc.2021.06.013_bib0003","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.cllc.2021.06.013_bib0004","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.06.013_bib0005","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2021.06.013_bib0006","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2021.06.013_bib0007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10066","key":"10.1016\/j.cllc.2021.06.013_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cllc.2021.06.013_bib0009","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"8","key":"10.1016\/j.cllc.2021.06.013_bib0010","doi-asserted-by":"crossref","first-page":"914","DOI":"10.5858\/arpa.2017-0584-RA","article-title":"Uncommon types of lung carcinoma with mixed histology","volume":"142","author":"Borczuk","year":"2018","journal-title":"Arch Pathol Lab"},{"issue":"12","key":"10.1016\/j.cllc.2021.06.013_bib0011","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/01.JTO.0000437008.00554.90","article-title":"Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma","volume":"8","author":"Vieira","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"6","key":"10.1016\/j.cllc.2021.06.013_bib0012","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/JTO.0b013e318292be18","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)","volume":"8","author":"Velcheti","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0013","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.lungcan.2016.05.013","article-title":"Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages","volume":"98","author":"Vieira","year":"2016","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2021.06.013_bib0014","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jtho.2017.03.005","article-title":"Pulmonary sarcomatoid carcinomas commonly harbor either potentially targetable genomic alterations or high tumor mutational burden as observed by comprehensive genomic profiling","volume":"12","author":"Schrock","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2021.06.013_bib0015","doi-asserted-by":"crossref","first-page":"E456","DOI":"10.1016\/j.cllc.2020.02.022","article-title":"Relashionship between programmed death receptor-ligand 1 expression and response to checkpoint inhibitor immunotherapy in pulmondary sarcomatoid carcinoma: a pooled analysis","volume":"21","author":"Babacan","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.cllc.2021.06.013_bib0016","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/1759-7714.12505","article-title":"Case series of pleomorphic carcinomas of the lung treated with nivolumab","volume":"8","author":"Kanazu","year":"2017","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2021.06.013_bib0017","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2169\/internalmedicine.0890-18","article-title":"Rapid and Long-term response of pulmonary pleomorphic carcinoma to nivolumab","volume":"58","author":"Senoo","year":"2019","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.cllc.2021.06.013_bib0018","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1159\/000489392","article-title":"Successful treatment of pulmonary pleomorphic carcinoma with nivolumab: a case report","volume":"11","author":"Fujimoto","year":"2018","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0019","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/1759-7714.12557","article-title":"Pulmonary pleomorphic carcinoma with few PD-1-positive immune cells and regulatory T cells that showed a complete response to nivolumab","volume":"9","author":"Okamura","year":"2018","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2021.06.013_bib0020","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/1759-7714.13029","article-title":"Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence","volume":"10","author":"Yaguchi","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.cllc.2021.06.013_bib0021","first-page":"310","article-title":"Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review","volume":"26","author":"Kotlowska","year":"2019","journal-title":"Respir Med Case Reports"},{"issue":"2","key":"10.1016\/j.cllc.2021.06.013_bib0022","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1159\/000479552","article-title":"The successful treatment of pulmonary pleomorphic carcinoma with pembrolizumab: a case report","volume":"10","author":"Matsumoto","year":"2017","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0023","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000492666","article-title":"Nivolumab-induced impressive response of refractory pulmonary sarcomatoid carcinoma with brain metastasis","volume":"11","author":"Salati","year":"2018","journal-title":"Case Rep Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2021.06.013_bib0024","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jtho.2020.01.014","article-title":"Efficacy of immune checkpoint inhibitors in lung sarcomatoid carcinoma","volume":"15","author":"Domblides","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"10","key":"10.1016\/j.cllc.2021.06.013_bib0025","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden and response to immunotherapy n patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.cllc.2021.06.013_bib0026","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1002\/cncr.24498","article-title":"Pulmonary neuroendocrine\/carcinoid tumors: a review article","volume":"115","author":"Bertino","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2021.06.013_bib0027","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.lungcan.2017.03.006","article-title":"PD-L1 expression in neuroendocrine tumors of the lung","volume":"108","author":"Tsuruoka","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2021.06.013_bib0028","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2019.02.022","article-title":"Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC)","volume":"130","author":"Hermans","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2021.06.013_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920937972","article-title":"PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 \u201cEPNEC\u201d study","volume":"12","author":"Arpin","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0030","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1007\/s12253-020-00832-0","article-title":"PD-L1 expression in small cell and large cell neuroendocrine carcinomas of lung: an immunohistochemical study with review of literature","volume":"26","author":"Guleria","year":"2020","journal-title":"Pathol Oncol Res"},{"issue":"6","key":"10.1016\/j.cllc.2021.06.013_bib0031","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jtho.2018.02.002","article-title":"New insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management","volume":"13","author":"Derks","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.cllc.2021.06.013_bib0032","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000488996","article-title":"Immune checkpoint inhibitors in the treatment of patients with neuroendocrine neoplasia","volume":"41","author":"Weber","year":"2018","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.cllc.2021.06.013_bib0033","article-title":"Nonsmall cell lung carcinoma with giant cell features expressing programmed death-ligand 1: a report of a patient successfully treated with pembrolizumab","author":"Nakayama","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.cllc.2021.06.013_bib0034","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.lungcan.2018.12.006","article-title":"Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab","volume":"128","author":"Mauclet","year":"2019","journal-title":"Lung Cancer"},{"issue":"75","key":"10.1016\/j.cllc.2021.06.013_bib0035","first-page":"1","article-title":"Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden","volume":"5","author":"Wang","year":"2017","journal-title":"J ImmunoTher Cancer"},{"issue":"15","key":"10.1016\/j.cllc.2021.06.013_bib0036","doi-asserted-by":"crossref","first-page":"S702","DOI":"10.1016\/j.jtho.2016.11.923","article-title":"Efficacy of immune checkpoint inhibitors in large cell neuroendocrine lung cancer: results from a French retrospective cohort","volume":"12","author":"Levra","year":"2017","journal-title":"P1.07-012, J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2021.06.013_bib0037","first-page":"59","article-title":"Effectiveness of nivolumab in large-cell neuroendocrine carcinoma of the lung -a report of 2 cases","volume":"44","author":"Daido","year":"2017","journal-title":"[Article in Japanese] Gan To Kagaku Ryoho"},{"issue":"18","key":"10.1016\/j.cllc.2021.06.013_bib0038","doi-asserted-by":"crossref","first-page":"14738","DOI":"10.18632\/oncotarget.24553","article-title":"Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status","volume":"9","author":"Chauhan","year":"2018","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.cllc.2021.06.013_bib0039","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.21037\/apm-20-1667","article-title":"Large cell neuroendocrine carcinoma of the lungs: case report and literature review","volume":"9","author":"Han","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.cllc.2021.06.013_bib0040","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3892\/mco.2020.2045","article-title":"Large cell neuroendocrine carcinoma of the lung that responded to nivolumab: a case report","volume":"13","author":"Sato","year":"2020","journal-title":"Mole Clin Oncol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0041","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1111\/1759-7714.13471","article-title":"Long-term survivor of pulmonary combined large cell neuroendocrine carcinoma treated with nivolumab","volume":"11","author":"Oda","year":"2020","journal-title":"Thora Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2021.06.013_bib0042","article-title":"Brief report on efficacy of nivolumab in patients with previously treated advanced large-cell neuroendocrine cancer of the lung","volume":"2","author":"Agar","year":"2020","journal-title":"J Thorac Oncol Clin Res Rep"},{"issue":"2","key":"10.1016\/j.cllc.2021.06.013_bib0043","doi-asserted-by":"crossref","first-page":"365","DOI":"10.31557\/APJCP.2021.22.2.365","article-title":"Role of immunotherapy in stage IV large cell neuroendocrine carcinoma of the lung","volume":"22","author":"Komiya","year":"2021","journal-title":"JAsian Pac J Cancer Prev"},{"key":"10.1016\/j.cllc.2021.06.013_bib0044","doi-asserted-by":"crossref","unstructured":"S. Sherman, O. Rotem, T. Shochat, et\u00a0al., Efficacy of immune check-points inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC), lung cancer 143 (2020) 40-46, https:\/\/doi.org\/10.1016\/j.lungcan.2020.03.008","DOI":"10.1016\/j.lungcan.2020.03.008"},{"issue":"5","key":"10.1016\/j.cllc.2021.06.013_bib0045","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdx368","article-title":"Pembrolizumab for patients with PD-L1\u2013positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study","volume":"28","author":"Mehnert","year":"2017","journal-title":"Ann Oncol"},{"issue":"15","key":"10.1016\/j.cllc.2021.06.013_bib0046","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.2019.37.15_suppl.4103","article-title":"A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC)","volume":"37","author":"Fottner","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.cllc.2021.06.013_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000530","article-title":"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.cllc.2021.06.013_bib0048","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A Phase II basket trial of dual anti-CTLA-4 and Anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with non-pancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"54","key":"10.1016\/j.cllc.2021.06.013_bib0049","first-page":"1","article-title":"Novel immunotherapy strategies for treatment of neuroendocrine neoplasms","volume":"5","author":"Al-Toubah","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0050","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.2147\/OTT.S164574","article-title":"Adenosquamous carcinoma of the lung","volume":"11","author":"Li","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.cllc.2021.06.013_bib0051","article-title":"PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer","volume":"7","author":"Shi","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.cllc.2021.06.013_bib0052","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/PAS.0000000000001400","article-title":"Heterogeneity of PD-L1 expression in lung mixed adenocarcinomas and adenosquamous carcinomas","volume":"44","author":"Marino","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.cllc.2021.06.013_bib0053","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1159\/000504473","article-title":"Combination of local ablative therapy and continuation of immune checkpoint inhibitor (ICI) therapy provides durable treatment response past oligometastatic progression in NSCLC: a case report","volume":"12","author":"Griswold","year":"2019","journal-title":"Case Rep Oncol"},{"issue":"81","key":"10.1016\/j.cllc.2021.06.013_bib0054","first-page":"1","article-title":"Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy","volume":"16","author":"Chen","year":"2018","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.cllc.2021.06.013_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001999","article-title":"Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of the lung","volume":"9","author":"Dudnik","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.cllc.2021.06.013_bib0056","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/annonc\/mdy293.001","volume":"9","author":"Yao","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0057","article-title":"Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations","author":"Ferrara","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.cllc.2021.06.013_bib0058","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/PO.20.00021","article-title":"Comparison of fast-progression, hyperprogressive disease, and early deaths in advanced non\u2013small-cell lung cancer treated with PD-1\/PD-L1 inhibitors or chemotherapy","volume":"4","author":"Ferrara","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"20","key":"10.1016\/j.cllc.2021.06.013_bib0059","article-title":"Genetic Heterogeneity of MET-Aberrant NSCLC and its impact on the outcome of immunotherapy","author":"Kron","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2021.06.013_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1758835920915983","article-title":"Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial)","volume":"12","author":"Gelsomino","year":"2020","journal-title":"Ther Adv Med Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421001807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730421001807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:11:16Z","timestamp":1761505876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730421001807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1525730421001807"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2021.06.013","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2021.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}